Conservation of mechanisms regulating emotional-like responses on spontaneous nicotine withdrawal in zebrafish and mammals.
Emotion
Hyperkatifeia
IEG
Memory
Nicotine dependence
TH
Journal
Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617
Informations de publication
Date de publication:
20 12 2021
20 12 2021
Historique:
received:
19
02
2021
revised:
19
04
2021
accepted:
21
04
2021
pubmed:
28
4
2021
medline:
16
2
2022
entrez:
27
4
2021
Statut:
ppublish
Résumé
Nicotine withdrawal syndrome is a major clinical problem. Animal models with sufficient predictive validity to support translation of pre-clinical findings to clinical research are lacking. We evaluated the behavioural and neurochemical alterations in zebrafish induced by short- and long-term nicotine withdrawal. Zebrafish were exposed to 1 mg/L nicotine for 2 weeks. Dependence was determined using behavioural analysis following mecamylamine-induced withdrawal, and brain nicotinic receptor binding studies. Separate groups of nicotine-exposed and control fish were assessed for anxiety-like behaviours, anhedonia and memory deficits following 2-60 days spontaneous withdrawal. Gene expression analysis using whole brain samples from nicotine-treated and control fish was performed at 7 and 60 days after the last drug exposure. Tyrosine hydroxylase (TH) immunoreactivity in pretectum was also analysed. Mecamylamine-precipitated withdrawal nicotine-exposed fish showed increased anxiety-like behaviour as evidenced by increased freezing and decreased exploration. Our findings show that nicotine withdrawal induced anxiety-like behaviour, cognitive alterations, gene expression changes and increase in pretectal TH expression, similar to those observed in humans and rodent models.
Sections du résumé
BACKGROUND
Nicotine withdrawal syndrome is a major clinical problem. Animal models with sufficient predictive validity to support translation of pre-clinical findings to clinical research are lacking.
AIMS
We evaluated the behavioural and neurochemical alterations in zebrafish induced by short- and long-term nicotine withdrawal.
METHODS
Zebrafish were exposed to 1 mg/L nicotine for 2 weeks. Dependence was determined using behavioural analysis following mecamylamine-induced withdrawal, and brain nicotinic receptor binding studies. Separate groups of nicotine-exposed and control fish were assessed for anxiety-like behaviours, anhedonia and memory deficits following 2-60 days spontaneous withdrawal. Gene expression analysis using whole brain samples from nicotine-treated and control fish was performed at 7 and 60 days after the last drug exposure. Tyrosine hydroxylase (TH) immunoreactivity in pretectum was also analysed.
RESULTS
Mecamylamine-precipitated withdrawal nicotine-exposed fish showed increased anxiety-like behaviour as evidenced by increased freezing and decreased exploration.
CONCLUSIONS
Our findings show that nicotine withdrawal induced anxiety-like behaviour, cognitive alterations, gene expression changes and increase in pretectal TH expression, similar to those observed in humans and rodent models.
Identifiants
pubmed: 33905756
pii: S0278-5846(21)00093-2
doi: 10.1016/j.pnpbp.2021.110334
pmc: PMC8380689
mid: NIHMS1698024
pii:
doi:
Substances chimiques
Receptors, Nicotinic
0
Tyrosine 3-Monooxygenase
EC 1.14.16.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
110334Subventions
Organisme : NIDA NIH HHS
ID : U01 DA044400
Pays : United States
Informations de copyright
Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.
Références
Psychopharmacology (Berl). 2003 Jul;168(3):280-92
pubmed: 12712232
Neuropharmacology. 2010 Jun;58(7):1140-6
pubmed: 20153341
Nat Protoc. 2010 Nov;5(11):1786-99
pubmed: 21030954
Nicotine Tob Res. 2011 May;13(5):301-12
pubmed: 21385906
Psychopharmacology (Berl). 2005 Mar;178(2-3):211-22
pubmed: 15338107
Handb Exp Pharmacol. 2009;(192):335-67
pubmed: 19184655
Sci Rep. 2018 Apr 12;8(1):5938
pubmed: 29651048
Zebrafish. 2017 Jun;14(3):197-208
pubmed: 28459655
Eur J Neurosci. 2020 Jul;52(1):2604-2613
pubmed: 31597204
Neurotoxicol Teratol. 2017 Jan - Feb;59:62-67
pubmed: 27916716
Eur Neuropsychopharmacol. 2015 Aug;25(8):1300-13
pubmed: 26003081
Am J Public Health. 2003 Jun;93(6):994-8
pubmed: 12773367
Front Cell Neurosci. 2019 Apr 30;13:158
pubmed: 31114482
Drug Alcohol Depend. 2015 Apr 1;149:158-65
pubmed: 25697911
Brain Res Bull. 2019 Mar;146:94-103
pubmed: 30584905
J Exp Biol. 2008 May;211(Pt 10):1623-34
pubmed: 18456890
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Dec 3;55:26-39
pubmed: 24657522
PLoS One. 2013 May 13;8(5):e63319
pubmed: 23675478
Neuropharmacology. 2018 Jan;128:86-95
pubmed: 28986279
Synapse. 2014 Nov;68(11):508-17
pubmed: 25042794
Addict Biol. 2016 Jan;21(1):49-60
pubmed: 25138642
Psychopharmacology (Berl). 2014 May;231(9):1975-85
pubmed: 24311357
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Dec 3;55:80-6
pubmed: 24681194
Neuroscience. 2009 Sep 15;162(4):1174-86
pubmed: 19465085
PLoS One. 2013 Jul 24;8(7):e69453
pubmed: 23894483
J Neurosci. 2014 Feb 26;34(9):3142-60
pubmed: 24573274
Eur J Neurosci. 2002 Nov;16(9):1633-46
pubmed: 12431215
Physiol Behav. 2008 Jan 28;93(1-2):160-71
pubmed: 17889042
J Neurochem. 2004 Jul;90(1):40-9
pubmed: 15198665
Alcohol. 2016 Feb;50:83-9
pubmed: 26781213
Psychopharmacology (Berl). 2014 Dec;231(24):4681-93
pubmed: 24862365
Genes Brain Behav. 2009 Aug;8(6):586-99
pubmed: 19243447
Br J Pharmacol. 2018 Jun;175(11):1944-1956
pubmed: 28585241
Neurotoxicol Teratol. 2017 Jul;62:27-33
pubmed: 28438663
J Pharmacol Exp Ther. 2003 Nov;307(2):526-34
pubmed: 12970387
Front Behav Neurosci. 2018 Apr 25;12:79
pubmed: 29755331
Behav Brain Res. 2010 Apr 2;208(2):371-6
pubmed: 20006651
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):105-111
pubmed: 28602852
Behav Brain Res. 2009 Dec 14;205(1):38-44
pubmed: 19540270
Physiol Behav. 2008 Oct 20;95(3):408-12
pubmed: 18671990
Neurotoxicol Teratol. 2004 Nov-Dec;26(6):725-9
pubmed: 15451036
Eur Neuropsychopharmacol. 2015 Oct;25(10):1775-86
pubmed: 26141510
Pharmacol Biochem Behav. 2019 Aug;183:1-5
pubmed: 31145916
Neurosci Biobehav Rev. 2015 Nov;58:168-85
pubmed: 26054790
PLoS One. 2011;6(5):e20002
pubmed: 21647443
J Abnorm Psychol. 2015 Feb;124(1):215-25
pubmed: 25384069
Acta Biochim Biophys Sin (Shanghai). 2007 May;39(5):384-90
pubmed: 17492136
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jun 8;100:109873
pubmed: 31981718
Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3159-68
pubmed: 18640919
Behav Brain Res. 2015 Jan 1;276:161-70
pubmed: 24598276
Dev Dyn. 2009 Apr;238(4):980-92
pubmed: 19301390
BMC Evol Biol. 2019 Jan 30;19(1):38
pubmed: 30700248
Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):360-8
pubmed: 17582477
Toxicol Appl Pharmacol. 2009 Aug 15;239(1):1-12
pubmed: 19121331
Neuropharmacology. 2002 Oct;43(5):857-67
pubmed: 12384171
Biochem Pharmacol. 2012 Aug 1;84(3):352-65
pubmed: 22580045
Cell. 2015 Aug 13;162(4):712-25
pubmed: 26276628
Subst Use Misuse. 2008;43(3-4):271-84
pubmed: 18365930
J Neuroimmunol. 2018 Oct 15;323:94-104
pubmed: 30196840
Lab Anim. 2014 Oct;48(4):328-37
pubmed: 24939904
Behav Brain Res. 2011 Jun 1;219(2):234-9
pubmed: 21255611
Pharmacol Biochem Behav. 2015 Dec;139 Pt B:112-20
pubmed: 25643654
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18662-7
pubmed: 19858493
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:161-170
pubmed: 30946939
Genes Brain Behav. 2016 Jan;15(1):89-107
pubmed: 26351737
Behav Brain Res. 2013 Jan 1;236(1):258-269
pubmed: 22974549
Mol Pharmacol. 2014 Sep;86(3):306-17
pubmed: 25002271
J Neurosci. 2015 Nov 18;35(46):15291-4
pubmed: 26586817
Pharmacol Biochem Behav. 2013 May;106:137-42
pubmed: 23558086
J Pharmacol Exp Ther. 2003 Sep;306(3):1068-76
pubmed: 12805481
Mol Neurobiol. 2021 Apr;58(4):1650-1663
pubmed: 33236326
Health Psychol. 2000 Jan;19(1S):17-31
pubmed: 10709945
Nature. 1998 May 7;393(6680):76-9
pubmed: 9590692
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21171-6
pubmed: 24327734
Nicotine Tob Res. 2004 Apr;6(2):249-67
pubmed: 15203798
Zebrafish. 2007 Spring;4(1):21-40
pubmed: 18041940
Pharmacol Biochem Behav. 2017 Jun;157:1-8
pubmed: 28408289
J Pharmacol Exp Ther. 1999 Jun;289(3):1545-52
pubmed: 10336551
Eur J Neurosci. 2014 Jul;40(1):2225-40
pubmed: 24738729
J Comp Neurol. 2007 Oct 20;504(6):631-45
pubmed: 17722029
Pharmacol Rev. 2021 Jan;73(1):163-201
pubmed: 33318153
Behav Brain Res. 2013 Sep 1;252:204-13
pubmed: 23756142
Eur J Pharmacol. 2011 Mar 25;655(1-3):52-8
pubmed: 21262222
ILAR J. 2012;53(2):192-204
pubmed: 23382350
Elife. 2020 Mar 25;9:
pubmed: 32209227
Nat Rev Drug Discov. 2007 Sep;6(9):746-62
pubmed: 17690709
Eur J Pharmacol. 2005 May 23;516(1):40-5
pubmed: 15922326
Behav Brain Res. 2008 Mar 17;188(1):168-77
pubmed: 18054804